High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer

BACKGROUND. The present study was performed to determine whether the human epidermal growth factor receptor-related 2 (HER2)/centromeric probe for chromosome 17 fluorescence in situ hybridization (FISH) ratio is a predictor of a pathologic complete response (pCR), recurrence-free survival (RFS), and...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Oncologist
Prif Awduron: Kogawa, Takahiro, Fouad, Tamer M., Liu, Diane D., Wu, Jimin, Shen, Yu, Masuda, Hiroko, Fujii, Takeo, Chavez-MacGregor, Mariana, Alvarez, Ricardo H., Hortobágyi, Gabriel N., Valero, Vicente, Ueno, Naoto T.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: AlphaMed Press 2016
Pynciau:
Breast Cancer
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4709200/
https://ncbi.nlm.nih.gov/pubmed/26659222
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0101
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg